{"filing":{"accession_number":"0001193125-26-335106","cik":"0001162194","ticker":"LAB","company_name":"STANDARD BIOTOOLS INC.","form":"8-K","filing_date":"2026-08-05","report_date":"2026-08-05","primary_document":"lab-20260805.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1162194/000119312526335106/lab-20260805.htm"},"events":[{"id":24738,"run_id":22431,"accession_number":"0001193125-26-335106","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"Standard BioTools issued a press release on August 5, 2026 disclosing financial results for the three and six months ended June 30, 2026, including revenue of $20.1 million for Q2 2026, gross margins of 52.4%, operating loss of $25.4 million, and adjusted EBITDA loss of $2.5 million.","company_name":"STANDARD BIOTOOLS INC.","ticker":"LAB","filing_date":"2026-08-05","form":"8-K","submitted_at":null,"items":[{"id":25396,"accession_number":"0001193125-26-335106","item_number":"2.02","item_title":"Results of Operations and Financial Condition","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Standard BioTools issued a press release on August 5, 2026 disclosing financial results for the three and six months ended June 30, 2026, including revenue of $20.1 million for Q2 2026, gross margins, operating expenses, net loss, and adjusted EBITDA. This is a standard quarterly earnings release filed under Item 2.02 (Results of Operations and Financial Condition), with the press release attached as Exhibit 99.1.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-07T02:17:30.606318+00:00","company_name":"","ticker":null,"filing_date":""},{"id":25397,"accession_number":"0001193125-26-335106","item_number":"7.01","item_title":"Regulation FD Disclosure","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Standard BioTools disclosed second quarter 2026 financial results via press release dated August 5, 2026, including revenue of $20.1 million, gross margins of 52.4%, operating loss of $25.4 million, and adjusted EBITDA loss of $2.5 million. The filing explicitly incorporates the press release under Item 7.01 (Regulation FD Disclosure), and the exhibit contains a complete earnings announcement with detailed financial tables and management commentary. This is a standard quarterly earnings release material to investors assessing the company's operational performance.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-07T02:17:30.606318+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":25396,"accession_number":"0001193125-26-335106","item_number":"2.02","item_title":"Results of Operations and Financial Condition","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Standard BioTools issued a press release on August 5, 2026 disclosing financial results for the three and six months ended June 30, 2026, including revenue of $20.1 million for Q2 2026, gross margins, operating expenses, net loss, and adjusted EBITDA. This is a standard quarterly earnings release filed under Item 2.02 (Results of Operations and Financial Condition), with the press release attached as Exhibit 99.1.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-07T02:17:30.606318+00:00","company_name":"STANDARD BIOTOOLS INC.","ticker":"LAB","filing_date":"2026-08-05"},{"id":25397,"accession_number":"0001193125-26-335106","item_number":"7.01","item_title":"Regulation FD Disclosure","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Standard BioTools disclosed second quarter 2026 financial results via press release dated August 5, 2026, including revenue of $20.1 million, gross margins of 52.4%, operating loss of $25.4 million, and adjusted EBITDA loss of $2.5 million. The filing explicitly incorporates the press release under Item 7.01 (Regulation FD Disclosure), and the exhibit contains a complete earnings announcement with detailed financial tables and management commentary. This is a standard quarterly earnings release material to investors assessing the company's operational performance.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-07T02:17:30.606318+00:00","company_name":"STANDARD BIOTOOLS INC.","ticker":"LAB","filing_date":"2026-08-05"}]}